Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CCR5 | P51681 | 7/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.49 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130312 | 0.97 | RECQL (0.62) | LMNACCR5RECQLSMN1; SMN2KMT2A | |
| SCHEMBL4696193 | 0.88 | SMN1; SMN2 (0.67) | LMNACCR5RECQLSMN1; SMN2KMT2A | |
| SCHEMBL4696189 | 0.88 | SMN1; SMN2 (0.67) | LMNACCR5RECQLSMN1; SMN2KMT2A | |
| SCHEMBL4130344 | 0.85 | CCR5 (0.54) | LMNACCR5RECQLSMN1; SMN2KCNQ3 | |
| SCHEMBL14420637 | 0.85 | CCR5 (0.54) | LMNACCR5RECQLSMN1; SMN2KCNQ3 | |
| SCHEMBL4138087 | 0.85 | SMN1; SMN2 (0.63) | LMNACCR5RECQLSMN1; SMN2KMT2A | |
| SCHEMBL13326739 | 0.85 | TDP1 (0.65) | LMNACCR5RECQLSMN1; SMN2KCNQ3 | |
| SCHEMBL9830370 | 0.85 | SMN1; SMN2 (0.63) | LMNACCR5RECQLSMN1; SMN2KMT2A | |
| SCHEMBL1573757 | 0.83 | RECQL (0.59) | LMNACCR5RECQLSMN1; SMN2KMT2A | |
| SCHEMBL1573959 | 0.83 | RECQL (0.59) | LMNACCR5RECQLSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117859-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117859-A1 | Heterocyclic antiviral compounds | CCR5, ACKR3, CXCR1 | LMNA 4348/4885CCR5 1/4885RECQL 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.